Jana M. Raessler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jana M. Raessler has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Mackin
College of Veterinary Medicine, Mississippi State University , Starkville, Mississippi
1 shared publication - Brian W. Smith
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA
1 shared publication - Carolyn M. Poutasse
California Air Resources Board, Sacramento, CA, 95814, USA
1 shared publication - Isabella M. Nelson
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA
1 shared publication - Joana Hernandez Vazquez
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA
1 shared publication - Julie Beth Herbstman
Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, 722 W 168th St, New York, NY 10032, USA
1 shared publication
Latest Publications
- Open Access
- 17 September 2025
- Published by Elsevier in Environmental Research
- Vol. 286 (Pt 2) , 122885
Unraveling the environmental links to feline hyperthyroidism: Insights from silicone passive samplers
- 17 September 2025
- Published by Elsevier in Environmental Research
- Vol. 286 (Pt 2) , 122885
Open AccessUnraveling the environmental links to feline hyperthyroidism: Insights from silicone passive samplers
- Open Access
Influence of Feeding on IL-2 Gene Expression and Peak Blood Cyclosporine Concentration in Healthy Dogs Administered Oral Cyclosporine
The administration of modified cyclosporine with food has been reported to decrease oral bioavailability. The objective of this study was to compare the pharmacodynamic effects of oral modified cyclosporine in healthy dogs when administered with and without food. In this randomized, crossover study, eight client-owned dogs received a commercial formulation of modified cyclosporine (median dose, 3.5 mg/kg PO q12h) with food (fed phase) or one hour before food (fasted phase) for 7 days. Two hour post capsule administration was used as the expected time of peak cyclosporine concentration. Peak cyclosporine blood concentration measured by antibody-conjugated magnetic immunoassay and interleukin-2 (IL-2) mRNA expression assessed by quantitative reverse transcription PCR (qRT-PCR) were measured at baseline, seventh day of each phase, and after a 21-day washout. Three dogs were withdrawn due to refractory anorexia. For the five dogs that completed this study, no difference in cytokine expression (p = 0.9) was found when comparing qRT-PCR values between the fed and fasted phase. All dogs achieved post-treatment IL-2 expression corresponding with “moderate” levels of immunosuppression or higher after both phases. No difference in peak blood cyclosporine concentration was found between the 7th day of the fed phase (median, 2042; range, 1484–2100 ng/mL) and fasted phase (median, 1990; range 1137–2100 ng/mL; p = 0.8). Feeding dogs at the time of the administration of oral modified cyclosporine can achieve similar suppression of IL-2 expression and blood concentrations two hours post drug administration as compared to when the drug is administered without food.
Open AccessInfluence of Feeding on IL-2 Gene Expression and Peak Blood Cyclosporine Concentration in Healthy Dogs Administered Oral Cyclosporine
The administration of modified cyclosporine with food has been reported to decrease oral bioavailability. The objective of this study was to compare the pharmacodynamic effects of oral modified cyclosporine in healthy dogs when administered with and without food. In this randomized, crossover study, eight client-owned dogs received a commercial formulation of modified cyclosporine (median dose, 3.5 mg/kg PO q12h) with food (fed phase) or one hour before food (fasted phase) for 7 days. Two hour post capsule administration was used as the expected time of peak cyclosporine concentration. Peak cyclosporine blood concentration measured by antibody-conjugated magnetic immunoassay and interleukin-2 (IL-2) mRNA expression assessed by quantitative reverse transcription PCR (qRT-PCR) were measured at baseline, seventh day of each phase, and after a 21-day washout. Three dogs were withdrawn due to refractory anorexia. For the five dogs that completed this study, no difference in cytokine expression (p = 0.9) was found when comparing qRT-PCR values between the fed and fasted phase. All dogs achieved post-treatment IL-2 expression corresponding with “moderate” levels of immunosuppression or higher after both phases. No difference in peak blood cyclosporine concentration was found between the 7th day of the fed phase (median, 2042; range, 1484–2100 ng/mL) and fasted phase (median, 1990; range 1137–2100 ng/mL; p = 0.8). Feeding dogs at the time of the administration of oral modified cyclosporine can achieve similar suppression of IL-2 expression and blood concentrations two hours post drug administration as compared to when the drug is administered without food.